Ionis Pharmaceuticals (IONS) news
Recent news
Adarx Pharma said to guide IPO pricing to top of range or above
ADARx Pharmaceuticals is expected to price its upcoming Nasdaq IPO at or above the top of its $15–$17 per share range, according to recent market signals and investor sentiment. The company is offering 21.875 million shares in the offering, which could raise up to $350 million and value the firm at…
AInvest Wire · Sep 24, 2026Ionis Pharma shares gain 8% after positive topline results
AInvest Wire · Sep 22, 2026OTSuka's Ulefnersen meets primary endpoint in phase 3 trial
Otsuka Pharmaceutical Co., Ltd. has announced that ulefnersen, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, has met its primary endpoint in a phase 3 clinical trial. The trial, conducted in multiple countries…
AInvest Wire · Sep 22, 2026Ionis Pharmaceuticals, - Ulefsen demonstrates favorable safety and tolerability profile
Ionis Pharmaceuticals has reported that Ulefsen, an investigational therapy, has demonstrated a favorable safety and tolerability profile in clinical trials. These findings are significant as they support the continued development of the compound for its intended therapeutic use. The data indicate…
AInvest Wire · Sep 22, 2026Ionis reports positive topline from phase 3 fusion study
AInvest Wire · Sep 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.